Valuation: NOVARTIS

Market Cap 28TCr 25TCr 23TCr 21TCr 40TCr 26,89300Cr 41TCr 2,71800Cr 1,06700Cr 13,24900Cr 1,05900Cr 1,03600Cr 45,54600Cr P/E 2026 *
21.5x
P/E 2027 * 18.2x
Enterprise Value 31TCr 27TCr 25TCr 23TCr 44TCr 29,94800Cr 45TCr 3,02700Cr 1,18900Cr 14,75300Cr 1,17900Cr 1,15300Cr 50,71900Cr EV / Sales 2026 *
5.52x
EV / Sales 2027 * 5.15x
Free-Float
91.66%
Yield 2026 *
2.86%
Yield 2027 * 2.95%
Manager TitleAgeSince
Chief Executive Officer 50 01/02/2018
Director of Finance/CFO - 16/03/2026
Chief Tech/Sci/R&D Officer 64 16/05/2022
Director TitleAgeSince
Director/Board Member 67 01/01/2015
Director/Board Member 69 01/01/2016
Director/Board Member 61 01/01/2016
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+50.33%+162.29% 1,08500Cr
-0.82%-2.30%+62.97%+61.11% 62TCr
-0.73%-4.98%+27.22%+84.46% 44TCr
+0.33%-1.17%+27.98%+26.90% 33TCr
-3.89%-11.22%+20.78%+26.07% 28TCr
+0.66%-1.42%-29.26%-39.30% 22TCr
-0.06%-2.88%+20.98%+61.70% 20TCr
-3.72%-1.10%+13.35%+71.53% 17TCr
-0.33%-0.62%-6.25%-32.26% 14TCr
Average -0.88%-3.30%+20.90%+46.94% 38.65TCr
Weighted average by Cap. -0.59%-3.08%+34.53%+80.15%

Financials

2026 *2027 *
Net sales 5.69TCr 4.97TCr 4.59TCr 4.24TCr 8.04TCr 5,42300Cr 8.18TCr 55TCr 22TCr 2,67200Cr 21TCr 21TCr 9,18500Cr 6.03TCr 5.27TCr 4.87TCr 4.49TCr 8.53TCr 5,75100Cr 8.67TCr 58TCr 23TCr 2,83300Cr 23TCr 22TCr 9,74000Cr
Net income 1.41TCr 1.23TCr 1.14TCr 1.05TCr 1.99TCr 1,34300Cr 2.02TCr 14TCr 5.33TCr 66TCr 5.29TCr 5.17TCr 2,27400Cr 1.56TCr 1.37TCr 1.26TCr 1.17TCr 2.21TCr 1,49200Cr 2.25TCr 15TCr 5.92TCr 73TCr 5.87TCr 5.75TCr 2,52700Cr
Net Debt 3.2TCr 2.8TCr 2.58TCr 2.39TCr 4.53TCr 3,05400Cr 4.6TCr 31TCr 12TCr 1,50500Cr 12TCr 12TCr 5,17300Cr 2.85TCr 2.5TCr 2.3TCr 2.13TCr 4.03TCr 2,72200Cr 4.1TCr 28TCr 11TCr 1,34100Cr 11TCr 10TCr 4,60900Cr
Logo NOVARTIS
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA